Sequent Scientific Ltd.

Expensive Star

Check Buy or Sell

155.65 2.40 (1.57%)

201.06% Gain from 52W Low

663.4K Volume

NSENov 27, 2020 03:31 PM

Watchlist

Portfolio

Alert

Share

3,865.9

Market Cap

Above industry Median

186

AVG Broker Target

19.5% upside

48.7

TTM PE Ratio

High in industry

1.9

TTM PEG Ratio

High in industry

4.9

Price to Book Ratio

Above industry Median

0.6

Beta 1Year

Very Low volatility



Sequent Scientific Ltd.    
09 Nov 2020
155.65
1.57%
buy
by Nirmal Bang Institutional
Target: 148 | Target met
Nirmal Bang Institutional
Sequent Scientific or SSL's 2QFY21 revenue at Rs3,463mn was higher than our estimate by 9.8%. Revenue grew by 21.8% YoY and 11.6% QoQ and was led by strong growth in the Emerging Markets (EM) and API sales. EM growth (135% QoQ) was led by the integration of Zoetis portfolio and revival in demand from the Poultry segment. Poultry demand had been subdued on account of COVID concerns. Revenue growth translated into EBITDA margin expansion of 47bps QoQ and 348bps YoY. The ROCE of the business is now in early 20s and operating cash flow is also robust. EBITDA to cash...
Sequent Scientific L.. has an average target of 186.00 from 2 brokers.
Sequent Scientific Ltd.    
09 Nov 2020
155.65
1.57%
buy
by BP Wealth
Target: 224 | Upside : 43.9%
BP Wealth
driven by positive operating leverage. During the quarter the company incurred one-time expenses of BSE code INR 90mn (onetime bonus and ESOPs of INR 52.1mn and INR 38.3mn related to discontinuation of Alivira France operations) under Exceptional item. SSL reported a PAT of INR 213mn compared to our estimate of INR 250mn. Adjusting onetime expenses, the Normalised PAT came in at INR297mn...
Sequent Scientific L.. has an average target of 186.00 from 2 brokers.
Sequent Scientific Ltd.    
22 Sep 2020
155.65
1.57%
buy
by BP Wealth
Target: 224 | Upside : 43.9%
BP Wealth
Sequent Scientific Ltd. has gained 128.56% in the last 1 Year
Sequent Scientific Ltd.    
31 Jul 2020
155.65
1.57%
buy
by Nirmal Bang Institutional
Target: 118 | Target met
Nirmal Bang Institutional
Sequent Scientific or SSLs 1QFY21 revenue at Rs3,103mn was higher than our estimate by 1.6%. Revenue grew by 11.6% YoY and was led by growth in both API and formulation sales across geographies, except the Emerging Markets (EM). There was a conscious decision to slow down in EMs considering the risk of bad debts. However, the situation is now normalizing and we should see sales in EMs back on track. Incrementally, the company has also entered into a distribution agreement with global animal health giant Zoetis for distribution of their products in India. The agreement gives SSL right to a portfolio of 13 brands (19 SKUs) amounting to Rs400mn in annual sales....
Sequent Scientific L.. has an average target of 186.00 from 2 brokers.
Sequent Scientific Ltd.    
13 May 2020
155.65
1.57%
buy
by Nirmal Bang Institutional
Target: 97 | Target met
Nirmal Bang Institutional
Sequent Scientific or SSL's 4QFY20 revenue at Rs3,006mn was lower than our estimate by 19.9%. Revenue grew by 6.6% YoY and was led by growth in both API and formulation sales across geographies except Emerging Markets (EM). Gross margin improved 140bps QoQ, primarily led by an increase in API sales and strong performance in Turkey, which is a higher margin business. With API business expected to get stronger from here on and no headwinds in Turkey, we should see margin further build up from current levels. The larger margin driver in the near to medium term would be the first generic launch of injectable in Europe. For FY21, the company has refrained from giving a...
Sequent Scientific Ltd. has gained 128.56% in the last 1 Year
Sequent Scientific Ltd.    
11 May 2020
155.65
1.57%
buy
by Nirmal Bang Institutional
Target: 97 | Target met
Nirmal Bang Institutional
Carlyle to acquire Sequent Timing not right, impacts deal valuation Global investment firm The Carlyle Group (US$224bn AUM) has made an open offer of Rs86 per share to acquire majority stake (up to 74%) in Sequent Scientific. The open offer is triggered by its share purchase agreement (SPA) to acquire 44.9% equity stake from the promoter group at Rs86 per share. The cumulative holding of the promoter group stands at 56.15%. The residual promoter holding of 11.29% (not offered so far under SPA) is held by Mr. K. R. Ravishankar. This may also be available to Carlyle post closure of the open offer (assuming Carlyle does not reach the threshold of 74%). Carlyle has also signed a SPA with...
default
Sequent Scientific L.. has an average target of 186.00 from 2 brokers.
Sequent Scientific Ltd.    
29 Jan 2020
155.65
1.57%
buy
by Nirmal Bang Institutional
Target: 97 | Target met
Nirmal Bang Institutional
Sequent Scientific or SSL's 3QFY20 revenue at Rs3,164mn was higher than our estimate by 7.4%. Revenue grew by 17% YoY and was led by growth in both API and formulation sales. API sales grew by 17.8% YoY and the formulations business grew by 16.5% YoY. Growth in API sales (20 -30%) should sustain at least until the end of FY21 as the company continues to build sales in regulated markets. The company is investing to implement additional API capacities with an objective to sustain growth trajectory...
Sequent Scientific Ltd. has gained 128.56% in the last 1 Year
Sequent Scientific Ltd.    
14 Nov 2019
155.65
1.57%
buy
by Nirmal Bang
Target: 97
Nirmal Bang
Sequent Scientific or SSL's 2QFY20 revenue at Rs2,842mn was in line with our estimate. Revenue grew by 14.5% YoY (cc) and was primarily led by growth in API sales. API sales grew by 30% YoY and now contribute 33% to total sales. The growth in API sales should sustain at least until the end of FY21 as the company expects to monetize its niche VMF (Veterinary master files) filings with low competitive intensity. About 5 of the 17 VMF filings of Sequent Formulations are niche, where SSL is the only filer. Formulation sales grew slower at 8% during the quarter as the company's largest geography Europe underperformed and declined 2.5% YoY. The decline in Europe is transient and was...
Nirmal Bang Institutional increased Accumulate price target of Sequent Scientific Ltd. to 148.0 on 09 Nov, 2020.
Sequent Scientific Ltd.    
14 Nov 2019
155.65
1.57%
buy
by Nirmal Bang Institutional
Target: 97
Nirmal Bang Institutional
Sequent Scientific or SSL's 2QFY20 revenue at Rs2,842mn was in line with our estimate. Revenue grew by 14.5% YoY (cc) and was primarily led by growth in API sales. API sales grew by 30% YoY and now contribute 33% to total sales. The growth in API sales should sustain at least until the end of FY21 as the company expects to monetize its niche VMF (Veterinary master files) filings with low competitive intensity. About 5 of the 17 VMF filings of Sequent Formulations are niche, where SSL is the only filer. Formulation sales grew slower at 8% during the quarter as the company's largest geography Europe underperformed and declined 2.5% YoY. The decline in Europe is transient and was...
Sequent Scientific Ltd. has gained 85.30% in the last 6 Months
Sequent Scientific Ltd.    
01 Aug 2019
155.65
1.57%
buy
by Nirmal Bang Institutional
Target: 116
Nirmal Bang Institutional
Sequent Scientific or SSLs 1QFY20 revenue at Rs2,780mn was below our estimate by 3.6%. On a QoQ basis, the performance was flattish across segments, except Emerging Markets formulations business, which grew by 14% QoQ. API sales (Rs900mn) were up 50% YoY but declined by 10% QoQ. The company is expecting API sales to exceed Rs 4000mn in FY20 and hence the run-rate in coming quarters should strengthen. To ensure enough capacities for the near to medium term the...
default
Sequent Scientific Ltd. is trading above all available SMAs